[HTML][HTML] Effectiveness of favipiravir in COVID-19: a live systematic review

B Özlüşen, Ş Kozan, RE Akcan, M Kalender… - European Journal of …, 2021 - Springer
We performed a systematic review and meta-analysis for the effectiveness of Favipiravir on
the fatality and the requirement of mechanical ventilation for the treatment of moderate to …

[HTML][HTML] Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial

M Bosaeed, A Alharbi, E Mahmoud, S Alrehily… - Clinical Microbiology …, 2022 - Elsevier
Objective To evaluate whether favipiravir reduces the time to viral clearance as documented
by negative RT-PCR results for severe acute respiratory syndrome coronavirus 2 in mild …

[HTML][HTML] Clinical efficacy and safety of antiviral drugs in the extended use against COVID-19: what we know so Far

MJ Hossain, T Jannat, SR Brishty, U Roy, S Mitra… - Biologics, 2021 - mdpi.com
Human beings around the globe have been suffering from a devastating novel pandemic
and public health emergency, coronavirus disease 2019 (COVID-19), for more than one and …

[HTML][HTML] Saliva metabolomic profile of COVID-19 patients associates with disease severity

N Saheb Sharif-Askari, NC Soares, HA Mohamed… - Metabolomics, 2022 - Springer
Abstract Introduction Coronavirus disease 2019 (COVID-19) is strongly linked to
dysregulation of various molecular, cellular, and physiological processes that change …

[HTML][HTML] A solvent-free HPLC method for the simultaneous determination of Favipiravir and its hydrolytic degradation product

YA Sharaf, MH Abd El-Fattah, HM El-Sayed… - Scientific Reports, 2023 - nature.com
Abstract During COVID-19 pandemic, Favipiravir (FPV) showed a great efficacy against
COVID-19 virus, it produced noticeable improvements in recovery of the patients. The aim of …

Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time …

A Yildiz Pekoz, O Akbal Dagistan, H Fael, M Culha… - Drug Delivery, 2022 - Taylor & Francis
Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients
infected with influenza virus and most recently with SARS-CoV-2. However, poor …

[HTML][HTML] A clinical insight on new discovered molecules and repurposed drugs for the treatment of COVID-19

S Banerjee, D Banerjee, A Singh, S Kumar, D Pooja… - Vaccines, 2023 - mdpi.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began churning out
incredulous terror in December 2019. Within several months from its first detection in …

[HTML][HTML] Favipiravir effectiveness and safety in hospitalized moderate-severe COVID-19 patients: observational prospective multicenter investigation in Saudi Arabia

S Al-Muhsen, NS Al-Numair… - Frontiers in …, 2022 - frontiersin.org
Objectives There are limited data on the efficacy and safety of favipiravir antiviral in
coronavirus disease 2019 (COVID-19), particularly in the more progressed disease phase …

[HTML][HTML] Towards the discovery of potential RdRp inhibitors for the treatment of COVID-19: Structure guided virtual screening, computational ADME and molecular …

A Alam, GP Agrawal, S Khan, H Khalilullah… - Structural Chemistry, 2022 - Springer
Abstract Coronavirus disease 2019 (COVID-19) has become a major challenge affecting
almost every corner of the world, with more than five million deaths worldwide. Despite …

[HTML][HTML] Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals

A Alamer, AR Almutairi, S Halloush, A Al-Jedai… - Saudi Pharmaceutical …, 2023 - Elsevier
Purpose We aimed to evaluate the cost effectiveness of Favipiravir treatment versus
standard of care (SC) in moderately to severely ill COVID-19 patients from the Saudi …